FindTrial
Sign In

Proteinuria in patients with bevacizumab (Avastin®): Identification of potential protein biomarker candidates for monitoring treatment side-effects

Proteinuria in patients with bevacizumab (Avastin®): Identification of potential protein biomarker candidates for monitoring treatment side-effects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-010857-10-AT
Enrollment
Unknown
Registered
2009-06-22
Start date
2009-07-23
Completion date
Unknown
Last updated
2014-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent malignant childhood central nervous system tumors

Interventions

Trade Name: Avastin Product Name: Avastin Pharmaceutical Form: Intravenous infusion

Sponsors

Universitätsklinik für Kinder- und Jugendheilkunde, Medizinsiche Universität Wien
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: • Female or male, aged between 0 and 19 years (at time of diagnosis) • Treatment with bevacizumab for therapeutic reasons • Written informed consent of patient/ parents Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: • Treatment with bevacizumab not indicated

Design outcomes

Primary

MeasureTime frame
Main Objective: Identification of marker proteins in patients with proteinuria and treatment with bevacizumab;Secondary Objective: ;Primary end point(s): Marker proteins in urine in patients with proteinuria under bevacizumab treatment identified—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026